Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to Roni Therapeutics' fourth quarter and four-year 2022 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we will ask for a limit of one question and one follow-up question per person. As a reminder, this call has been recorded today, Wednesday, March the 22nd, 2023. I would now like to turn the conference over to Lawrence Watts of Gil Martin Group. Please go ahead, sir. Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran, Chief Financial Officer, Spike Sanford, and Chief Scientific Officer, Amir Hashim. During this conference call, management will make forward-looking statements that are subject to risks, uncertainties, and assumptions, such as, but not limited to, those discussed in the risk factors section of the company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may cause actual events or results to differ materially from those described in these forward-looking statements. These statements may include, without limitation, statements regarding product development and clinical trials, product potential, device progress and performance, potential impact on patients, the regulatory environment, manufacturing progress, certain business strategies, capital resources, or operating performance. Actual results and the timing of events could differ materially from those projected in such forward-looking statements. With that, I will turn the call...